AMP releases guidelines for cytochrome P450 allele testing
William Aryitey |
The Association for Molecular Pathology (AMP) has recently published recommendations outlining cytochrome P450 2C19 (CYP2C19) genotyping. CYP2C19 is involved in the metabolism of many common drugs, which is why AMP’s Pharmacogenetics (PGx) Working Group wanted to define key points for clinical testing. “The purpose of this guideline is to aid clinical lab professionals when designing and validating clinical CYP2C19 genotyping assays, and to promote the standardization of testing across different laboratories,” says Victoria Pratt, first author of the recommendations, Associate Professor of Medical and Molecular Genetics at Indiana University School of Medical, and AMP PGx Working Group Chair. “As with all of our AMP guidelines, we base our recommendations on the evidence that has been published at the time, and what the evidence indicates is necessary to improve professional pharmacogenetics practice and patient care.”
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine